GAMMA ANTY-D ® 150

About Synthaverse

Synthaverse is a Polish biotech company with a mission to develop and deliver health solutions by combining scientific exploration with proprietary manufacturing expertise. The company has achieved commercial success with a portfolio of approved immunotherapy products, including treatments for bladder cancer and serological conflict, while simultaneously operating a contract manufacturing business unit. Its strategy hinges on leveraging its deep experience in biologics production to both advance its own pipeline and provide services to partners, creating a diversified revenue model. Founded in 2021 as a public entity, it seeks to push medical boundaries by continuously implementing new technologies and collaborating with scientific centers.

Therapeutic Areas

Other Immunotherapy in Serological Conflict (RhD prophylaxis) Drugs